| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 23, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/27/2021 | $2.50 → $8.00 | Neutral → Buy | Roth Capital |
| 8/10/2021 | $4.00 → $2.50 | Neutral | Roth Capital |
| 7/1/2021 | $8.00 | Buy | Guggenheim |
-Richard Pascoe appointed Chairman of the Board of Directors to spearhead the ongoing business development discussions NEW YORK, April 29, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on the current discussions of potential partnerships and collaborations and announced the appointment of Richard Pascoe as Chairman of the Board of Directors of Seelos to lead the ongoing strategic process and business development discussions and negotiations. Mr. Pascoe has served as member of the Seelos board since 2019
NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Margaret Dalesandro, Ph.D. to its Board of Directors. Dr. Margaret Dalesandro is an accomplished biopharmaceutical executive with over 30 years of experience in drug development and commercialization. She held senior executive leadership positions at ImClone Systems, Inc. and in her role as Vice President of Project, Portfol
NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year end 2020 business update. "This past year marked the most significant 12 months in Seelos Therapeutics' history despite being an otherwise challenging year due to the COVID-19 pandemic. We completed our safety trial for the intranasal ketamine program and began opening centers for our pivotal trial for Acute Suicidal Ideation and Behavior in patients with major depressive disorder. The trehalose program's pivotal study in ALS was accepted into the
NEW YORK, Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024, from its originally scheduled date of Friday, September 27, 2024, has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Monday, November 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting, August 19, 2
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on October 14, 2024, Seelos Therapeutics, Inc. (the "Company") received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Com
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was originally scheduled to be held on September 27, 2024, has been postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Friday, October 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting August 19, 2024, is unchanged and applies to the postponed Annual Meeting.
Roth Capital upgraded Seelos Therapeutics from Neutral to Buy and set a new price target of $8.00 from $2.50 previously
Roth Capital reiterated coverage of Seelos Therapeutics with a rating of Neutral and set a new price target of $2.50 from $4.00 previously
Guggenheim initiated coverage of Seelos Therapeutics with a rating of Buy and set a new price target of $8.00
-A single dose of SLS-004 produced a substantial increase in recovery of tyrosine hydroxylase-positive (TH+) dopaminergic neurons that are known to degenerate in patients with Parkinson's disease -Degeneration of TH+ midbrain dopaminergic neurons in patients with Parkinson's disease is attributed to lead to the cardinal Parkinsonian symptoms of tremor, rigidity, bradykinesia and postural disturbances -Seelos management will discuss additional information about this study during the Research and Development Update Conference Call and Webcast today, December 15th at 1pm ET NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET. Registration is available at https://lifescievents.com/event/seelos-therapeutics-kol-event/, and https://seelostherapeutics.com/registration-for-12-15-rd-update-webcast/. Itinerary for the Research and Develo
NEW YORK, Nov. 23, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET. "As we approach, what we believe to be, a very important and catalyst heavy 2023 for Seelos, it is important that we update our investors about our progress and strategic plans," said Raj Mehra Ph.D., Chairman and CEO
DEFA14A - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)
4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)
4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)
4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)
4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)
4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)
SC 13G - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)
SC 13G - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)
SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
Shares of VivoPower International PLC (NASDAQ:VVPR) rose sharply in today's pre-market trading after the company announced it secured an extension for a $34 million loan financing facility agreement. VivoPower International shares jumped 31.4% to $3.35 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Ampco-Pittsburgh Corporation (NYSE:AP) rose 72.6% to $1.32 in pre-market trading. Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares rose 40.4% to $0.9516 in pre-market trading after gaining 36% on Tuesday. NaaS Technology Inc. (NASDAQ:NAAS) gained 40% to $4.55 in pre-market trading after surging 68% on Tuesday. Soligenix, Inc. (NASDAQ:SNG